Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
192 participants
INTERVENTIONAL
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAK-875 25 mg
TAK-875
TAK-875 50 mg
TAK-875
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAK-875
TAK-875
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion Criteria
2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kisarazu-shi, Chiba, Japan
Matsuyama, Ehime, Japan
Fukuoka-shi Nishi-ku, Fukuoka, Japan
Kasuga-shi, Fukuoka, Japan
Naka, Ibaragi, Japan
Tsuchiura-shi, Ibaragi, Japan
Takamatsu, Kagawa-ken, Japan
Kyoto-shi Fushimi-ku, Kyoto, Japan
Nagasaki, Nagasaki, Japan
Kashihara-shi, Nara, Japan
Kashiwara-shi, Osaka, Japan
Osaka-shi Tsurumi-ku, Osaka, Japan
Sakai-shi Nishi-ku, Osaka, Japan
Shimotsuke-shi, Tochigi, Japan
Chiyoda-ku, Tokyo, Japan
Itabashi-ku, Tokyo, Japan
Ōta-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Toshima-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1124-1518
Identifier Type: REGISTRY
Identifier Source: secondary_id
JapicCTI-111604
Identifier Type: REGISTRY
Identifier Source: secondary_id
TAK-875/CCT-003
Identifier Type: -
Identifier Source: org_study_id